Tumor mesenchymal stem-like cell as a prognostic marker in primary glioblastoma by �쑄�꽑吏�
  
저작자표시-비영리-변경금지 2.0 대한민국 
이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 
l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.  
다음과 같은 조건을 따라야 합니다: 
l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건
을 명확하게 나타내어야 합니다.  
l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.  
저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 
이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다.  
Disclaimer  
  
  
저작자표시. 귀하는 원저작자를 표시하여야 합니다. 
비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 
변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. 
Tumor mesenchymal stem-like cell as 
a prognostic marker in primary 
glioblastoma
Seon-Jin Yoon
Department of Medicine
The Graduate School, Yonsei University
Tumor mesenchymal stem-like cell as 
a prognostic marker in primary 
glioblastoma
Directed by Professor Jong Hee Chang
The Master's Thesis 
submitted to the Department of Medicine,
the Graduate School of Yonsei University
in partial fulfillment of the requirements for the degree of 
Master of Medical Science
Seon-Jin Yoon
December 2015
This certifies that the Master's Thesis of 
Seon-Jin Yoon is approved.
[Signature]
------------------------------------
          Thesis Supervisor : Jong Hee Chang
[Signature]
------------------------------------
Thesis Committee Member#1 : Seok-Gu Kang
[Signature]
------------------------------------
Thesis Committee Member#2 : Se Hoon Kim
The Graduate School 
Yonsei University
December 2015
ACKNOWLEDGEMENTS
This thesis would not have been possible without the help and guidance of many 
professors, colleagues, and friends. 
I am grateful to Jong Hee Chang, the professor and the neurosurgeon of Severance 
hospital, for his guidance as the thesis supervisor to write an article regarding the 
prognosis of primary glioblastoma. His good surgical outcome adhering to a strict 
management of patients should have also contributed to a good result of this study. I 
am indebted to Seok-Gu Kang, the professor and the neurosurgeon of Severance 
hospital, for his fascinating ideas and leadership in basic research isolating cells 
from tumor tissues. I am quite impressed from Se Hoon Kim, the professor and the 
neuropathologist of Severance hospital, by his thoughtful interpretation of 
pathologic reports and advices on this research.
Research team, I want to thank Jin-Kyoung Shim, Ju-Hyung Moon, Tae-Hoon Roh, 
Ji-Hyun Lee, Eui-Hyun Kim, Jong Hee Chang, Sun Ho Kim, Yong-Kil Hong, Su 
Jae Lee, Yong Min Huh for their concrete efforts to understand glioblastoma. 
Neurosurgery department, Yong Gou Park, Sun Ho Kim, Seung Kon Huh, Do 
Heum Yoon, Jin Woo Chang, Dong Seok Kim, Keung Nyun Kim, Yoon Ha, Jae 
Whan Lee, Seong Yi, Kyu Won Shim, Won-Seok Chang, Euihyun Kim, Hyun Ho 
Jung, Dong Ah Shin, Eun Kyung Park, Keun Young Park, and professors at 
Gangnam severance hospital, Kyu Sung Lee, Yong Eun Cho, Jin Yang Joo, Keun 
Su Kim, Young Sul Yoon, Dong Kyu Chin, Sung Uk Kuk, Chang Ki Hong, Jeong 
Yoon Park, Yong Bae Kim , Joon Ho Chung, Kyung Hyun Kim. Tae Hoon Roh, Ju 
Hyung Moon, Hun Ho Park, Kyoung Su Sung. Yoon Ha who ignited my motivation 
to dip into clinical research, Dong A shin who inspired me to learn more about high 
performance computing for management of patient data.
Neurosurgery residents. Deokyoung Kim, Jang Hoon Kim, Tae Hun Moon, Han 
Joo Lee, Chang Gi Jang, Hyeong Seok Jeon, Dae Hwan Kim, Seong Jun Ryu, 
Sangman Park. Woo Sung Lee, Hyun-jin Han who worked together all days and 
nights to manage the soul of human.
I appreciate those who helped me to go further and perform clinical medicine after 
gradutation, Professor Yong Oock Kim, Woo Jin Hyung, Myongsei Sohn, So Yoon 
Kim, Seong Hye Kim, Jun Soo Shin, Jeong Mo Nam, Jong Wook Won, Hyun 
Chang Kim.
And patients with glioblatoma who suffered from the disease and made this 
research available.
Thank you for my father, mother, and my brother Seon Ho Yoon.
<TABLE OF CONTENTS>
ABSTRACT····································································1
I. INTRODUCTION ···························································2
II. MATERIALS AND METHODS ··········································4
1. Patient information ·························································4
2. Initial treatment ·····························································5
3. Isolation of tumor mesenchymal stem-like cell ·························6
4. Statistical analysis ··························································6
III. RESULTS ··································································7
1. Patient characteristics ······················································7
2. Patient survival······························································8
IV. DISCUSSION ·····························································12
V. CONCLUSION ····························································14
REFERENCES ································································15
ABSTRACT(IN KOREAN) ·················································19
LIST OF FIGURES
Figure 1. Kaplan-Meier estimates of overall survival in patients 
positive and negative for tumor mesenchymal stem-like cells
············································································7
LIST OF TABLES
Table 1. Demographic and clinical characteristics of patients with 
primary glioblastoma ·················································9
Table 2. Molecular marker expression stratified by isolation of 
tMSLCs··································································10
Table 3. Cox proportional hazard regression model of factors 
prognostic for overall survival in patients with primary 
glioblastoma ····························································11
1ABSTRACT
Tumor mesenchymal stem-like cell as 
a prognostic marker in primary glioblastoma
Seon-Jin Yoon
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Jong Hee Chang)
The isolation from brain tumors of tumor mesenchymal stem-like cells 
(tMSLCs) suggests that these cells play a role in creating a microenvironment 
for tumor initiation and progression.  The clinical characteristics of patients 
with primary glioblastoma (pGBM) positive for tMSLCs have not been 
determined.  This study analyzed samples from 82 patients with pGBM who 
had undergone tumor removal, pathological diagnosis, and isolation of 
tMSLC from April 2009 to October 2014.  Survival, extent of resection, 
molecular markers and tMSLC culture results were statistically evaluated.  
Median overall survival was 18.6 months, 15.0 months in tMSLC-positive 
and 29.5 months in tMSLC-negative patients (P=0.014).  Multivariate cox 
regression model showed isolation of tMSLC (OR=2.5, 95% CI=1.1~5.6, 
P=0.021) showed poor outcome while larger extent of resection (OR=0.5, 
95% CI=0.2~0.8, P=0.011) have association with better outcome.  The 
presence of tMSLCs isolated from the specimen of pGBM is associated with 
the survival of patient.
--------------------------------------------------------------------------------------
Key words : isolation, primary glioblastoma, prognosis, stroma, tumor 
mesenchymal stem-like cell
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I. Introduction
Glioblastomas (GBMs) are generated by interactions between cancer stem 
cells (CSCs) and stroma.1-3  The accumulation of molecular errors in CSCs 
initiates tumorigenesis, and these CSCs aggregate with stromal cells, which 
synergistically aggravate the disease.4,5  Mesenchymal stem-like cells 
(MSLCs) have been isolated from normal brain6,7 and Lang et.al.,8 presented 
the isolation of mesenchymal stem cells (MSCs) from glioma for the first 
time.  In addition, tumor MSLCs (tMSLCs) have been isolated from several 
human brain tumors,2,9-11 suggesting that these cells play a role in creating a 
microenvironment conducive to brain tumor initiation and progression.2,12-14
GBMs can be grouped into several subtypes, based on molecular 
markers, gene expression profiles,15-19 and chromosomal aberration.20,21  
3Based on their genetic characteristics, GBMs can be divided into four types, 
with the mesenchymal type having the poorest prognosis.17,22,23  Several 
molecular markers have been shown to be related to survival benefits in 
patients with GBM, including O-6-methylguanine-DNA methyltransferase 
(MGMT) methylation and the isocitrate dehydrogenase (IDH) 1/2 mutation24-
26  The prognostic value of heterozygosity (LOH) at chromosomes 1p and 
19q, however, is unclear.27,28  Isolation of CSCs from primary GBM (pGBM) 
samples can also predict the natural course of pGBM.29  Although tumor 
stromal cells were found to have a significant impact on patient survival30,31
the clinical significance of isolation of tMSLCs, a type of stromal cells, from 
pGBM stroma has not been determined.  
We hypothesized that the presence of tMSLCs may aggravate the 
natural course of pGBM.  This study therefore assessed whether the presence 
of tMSLCs in pGBM patients has an effect on patient survival and prognosis.  
4II. Materials and methods
Patient information.  A total of 82 patients with pGBM who received standard 
therapy32 at two institutions (Severance Hospital, Yonsei University College of 
Medicine, and Seoul St. Mary's Hospital, The Catholic University of Korea 
College of Medicine) from April 2009 to October 2014 were included in this 
study (Table 1).  We followed up the cohort from previous report11 and added 
new additional patients which were not included in that report.11  Approval for 
harvest and investigation was obtained from the institutional review boards of 
the two institutions, and all patients provided written informed consent, as 
specified in the Declaration of Helsinki.  Specimens for isolation of tMSLCs 
were collected in the operating theater from patients undergoing surgery.  All 
surgical specimens were evaluated by two neuropathologists, who diagnosed 
each patient according to World Health Organization (WHO) classifications.33  
Survival, extent of resection, molecular markers, and tMSLC culture results 
were analyzed statistically.  Inclusion criteria were as follows: the first 
pathologic diagnosis of primary glioblastoma patients with the standard stupp 
protocol. Radiation dose of 60 Gy fractionated by 30 times. Stupp protocol 
within 2 weeks after the pathological diagnosis. Patients who expired during 
the standard treatment.  Excluded patients met following criteria: Recurred 
glioblastoma after previous surgery. Gliosarcoma. Non-standard dose for 
temozolomide administration. Hypofractionated radiotherapy. Poor hematologic 
profile that delayed normal course of standard treatment.  
5Initial treatment.  All patients underwent surgical resection, aimed at gross 
total resection of the tumor, followed by concurrent chemotherapy and 
radiotherapy and adjuvant chemotherapy.32  Gross total tumor resection was 
defined as macroscopic removal of 100% or above of the tumor mass found on 
magnetic resonance (MR) T1 enhanced and T2 images.34,35  Patients not suitable 
for total resection underwent subtotal resection, defined as removal of 
macroscopic tumor volume ≥90% but <100%, or partial resection, defined as 
removal of macroscopic tumor volume <90%.  The extent of tumor resection 
was estimated and classified by the neurosurgeons and rechecked by 
postoperative review of MR imaging (MRI) scans.  All patients received 
postoperative adjuvant radiotherapy with concomitant and adjuvant 
temozolomide (TMZ), as described previously.32  Each patient was offered 
standard therapy 32 after pathologic confirmation.  The only factors determining 
the continuation of standard treatment were patient tolerance (general condition, 
laboratory abnormalities such as hematologic problems), family agreement for 
the treatment, and patient survival.  The correlation between molecular markers 
(MGMT methylation, p53, 1p LOH, 19q LOH, Ki-67 indexIDH1 mutation) and 
survival was analyzed statistically.  MGMT methylation was assessed by 
polymerase chain reaction (PCR), and LOH at chromosomes 1p and 19 q by 
fluorescent in situ hybridization (FISH).  
6Isolation of tMSLCs.  tMSLCs with characteristics similar to MSCs have been 
isolated from brain tumor specimens.9-11  Tumor specimens removed surgically 
were cultured as described 9-11 and mesenchymal features were assayed, 
including plastic adhesion, trilineage differentiation, the presence of typical 
MSC surface markers (Positive for CD 105, CD 90, CD 72 and negative for CD 
45, CD 31, and NG2) and non-tumorigenic behavior.11,13,36
Statistical Analysis.  The primary outcome measure was median overall 
survival (OS), defined as the interval from date of surgery confirming the 
diagnosis of pGBM to the date of last follow-up visit or death.37  
Immunohistochemical analysis of p53 expression was defined as 
immunopositivity when the area with staining of ≥50% of cancer cells were 
found.  Ki 67 index was defined as immunopositive when the stained area 
exceeded 10 % or more.  Among clinically deemed primary glioblastoma, 5 
patients (6%) had mutation on IDH1.  They were not excluded from our study 
for comprehensive evaluation.  Because of small number of patients with IDH1 
mutation and previous reports about different clinical characteristics,38 they 
were not eligible for survival analysis and excluded from multivariate cox 
regression model.  Survival was analyzed by the Kaplan-Meier method and 
compared by the log-rank test.  Demographic characteristics were compared 
using Fisher’s exact test or t-test.  All statistical analyses were performed using 
SPSS 22 (IBM Korea, Seoul, Korea), with p values less than 0.05 were 
regarded as statistically significant.  
7III. Results
Patient characteristics.  Of the 82 patients with pGBM, 48 (59%) were 
positive and 34 (41%) negative for tMSLCs (Table 1), with no group 
differences in the extent of resection (P=0.471), age (P=0.683), and 
expression of specific molecular markers (IDH1, P=0.642; MGMT promoter, 
P=0.653; p53, P=0.522 for positivity P=0.492 for the percentage of 
immunohistochemistry; EGFR, P=0.161; Ki 67, P=0.739 for the number of 
immunostaining P=0.057 for the percentage of immunohistochemistry).  All 
of 48 tMSLCs isolated from specimens showed trilineage differentiation, 
expression of MSC surface markers, and adherence to a plastic plate without 
gliomagenesis.
Figure 1.  Kaplan-Meier estimates of overall survival in patients positive and 
negative for tMSLCs.  (p = 0.014 by the log-rank test).  
8Patient survival. At a medium follow-up of 11.1 months, 38 patients died. 
The median survival duration of all pGBM patients was 18.6 months, 15.0 
months in patients positive of tMSLCs and 29.5 months in patients negative 
for tMSLCs (P=0.014; Fig.1).  The 6, 12, and 24 month actuarial rates were 
86%, 60%, and 21% respectively, in patients positive for tMSLCs, and 93%, 
79%, and 61%, respectively, in patients negative for tMSLCs.  From 
univariate cox proportional regression, the only factor associated with poor 
survival was isolation of tMSLCs from the specimen (OR=2.4, 95% 
CI=1.2~5.1, P=0.017, Table 3). We included extent of resection, codeletion of 
1p19q, MGMT methylation, and Ki 67 index to a multivariate cox model with 
a result that isolation of tMSLCs (OR=2.5, 95% CI=1.1~5.6, P=0.021) was 
associated with poorer outcome and larger extent of resection had association 
with better prognosis (OR=0.5, 95% CI=0.2~0.8, P=0.011) while codeletion 
of 1p19q, MGMT methylation, and Ki 67 index does not differentiate survival 
of patients. 
9Table 1. Demographic and clinical characteristics of patients with pGBM
Characteristics
tMSLCs (+)
(N=48)
tMSLCs (-)
(N=34)
P value
Age (years) 0.683
Median 57.5 61
Range 28~85 24~80
Age – no. (%) 0.899
<50 years – no. (%) 9 (19) 6 (18)
≥50 years – no. (%) 39 (81) 28 (82)
Gender 0.110
Male – no. (%) 33 (69) 17 (50)
Female – no. (%) 15 (31) 17 (50)
Median survival (months) 15.0 29.5 0.014
  95% CI 9.6~20.4 11.9~47.1
Pathological diagnosis pGBM pGBM
Treatment OP/Stupp OP/Stupp
Extent of operation (Patients) 0.471
Gross total resection 29 (60) 19 (56)
Subtotal resection 18 (38) 12 (35)
Partial resection 1 (2) 3 (9)
Abbreviations: S.D, Standard deviation; IDH, Isocitrate dehydrogenase; LOH, Loss 
of heterozygosity; OP/Stupp, Operation followed by Stupp’s regimen;
10
Table 2. Molecular marker expression stratified by isolation of tMSLCs
Characteristics
tMSLCs (+)
(N=48)
tMSLCs (-)
(N=34)
P value
Molecular markers
  IDH1 0.642
    Wild type – no. (%) 39 (91) 26 (96)
    Mutation – no. (%) 4 (9) 1 (4)
    Missing data – no. (%) 5 (10) 7 (21)
1p19q 0.341
  No codeletion – no. (%) 37 (80) 30 (91)
  Median survival (months) 15.0 29.5 0.011
    95% CI 8.9~21.1 9.1~50.0
  Codeletion – no. (%) 9 (20) 3 (9)
  Median survival (months) 12.9 9.3 0.886
    95% CI 0.8~25.0 1.6~17.0
  Missing data – no. (%) 2 (4) 1 (3)
MGMT promoter 0.653
  Wild type – no. (%) 27 (59) 18 (53)
  Median survival (months) 15.0 NA 0.122
    95% CI 8.8~21.2 NA
  Methylated – no. (%) 19 (41) 16 (47)
    Median survival (months) 18.6 34.1 0.164
      95% CI 6.2~31.0 13.6~54.6
  Missing data – no. (%) 2 (4) 0 (0)
  p53 0.522
    IHC negative (< 50%) – no. (%) 23 (77) 13 (65)
    Median survival (months) 13.7 NA 0.324
      95% CI 9.8~17.6 NA
    IHC positive (≥ 50%) – no. (%) 7 (23) 7 (35)
    Median survival (months) 18.6 NA 0.704
      95% CI 9.9~27.3 NA
    IHC Mean ± S.D. 28.4±27.0 33.9±28.8 0.492
    Range (%) 1.5~85 2.5~90
  Missing data – no. (%) 18 (38) 14 (41)
  EGFR
    IHC Mean ± S.D. 1.9±1.1 2.3±0.9 0.161
    Range 0~3 0~3
  Missing data – no. (%) 6 (13) 7 (21)
Ki 67  0.739
    IHC negative (<10%) – no. (%) 5 (11) 3 (9)
    IHC positive (≥10%) – no. (%) 40 (89) 31 (91)
    IHC % Mean ± S.D. 22.6±14.1 30.1±20.2 0.057
    Range (%) 2~60 3~80
  Missing data – no. (%) 3 (6) 0 (0)
Abbreviations: S.D, Standard deviation; MGMT, O-6-methylguanine-DNA methyltransferase; 
EGFR, epidermal growth factor receptor;NA, Not available. 
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Table 3. Cox proportional hazard regression model of factors prognostic for 
overall survival in patients with pGBM
Characteristics
Univariate Multivariate
OR 95% CI P value OR 95% CI P value
Isolation of 
tMSLCs
2.4 1.2~5.1 0.017 2.5 1.1~5.6 0.021
Age ≥ 50 years 1.3 0.5~3.1 0.587
Extent of 
resection
0.7 0.4~1.1 0.151 0.5 0.2~0.8 0.011
IDH1 mutation 1.6 0.4~6.7 0.551
LOH 1p19q 1.3 0.6~3.0 0.532 1.1 0.4~2.6 0.869
MGMT 
methylation
0.8 0.4~1.6 0.522 0.9 0.4~1.9 0.792
p53 ≥ 50% 0.7 0.2~1.8 0.418
EGFR 1.1 0.7~1.5 0.782
Ki 67 index ≥ 
10%
3.3 0.5~24.7 0.235 5.4 0.7~42.0 0.107
Abbreviations: tMSLCs, tumor mesenchymal stem-like cells; IDH, isocitrate 
dehydrogenase;LOH, loss of heterozygosity; MGMT, O-6-methylguanine-DNA 
methyltransferase; EGFR, epidermal growth factor receptor; OR, odds ratio; CI, 
confidence interval
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IV. Discussion
MSLCs are cells with MSC-like properties that have been isolated from brain6,7, 
especially from brain tumors (tMSLCs).2,9-11,13,39  These cells possess MSC 
surface antigens, show trilineage differentiation, adhere to plastic plates, and are 
non-tumorigenic11,13,36  
  This study found that OS differed significantly between pGBM patients 
positive and negative for tMSLCs, suggesting that tMSLCs may play a role in 
the progression of pGBM.  Although the “seed and soil” concept of cancer 
biology was proposed more than 125 years ago,40-42 GBM tumorspheres (TS) 
have been demonstrated recently,43,44 with tMSLCs being a factor in this 
concept9-12  Although the exact function of tMSLCs in pGBM is not well 
understood, this study showed that tMSLCs were clinically important, in that 
they were prognostic of survival.  The next step should be to assess the 
interactions between the GBM TS and tMSLCs.  
Small number of patients (82 cases in total) recruited to this 
retrospective study is a limitation to interpret the results of this study.  Although 
we compiled as many patients as possible, only subgroup that meets strict 
inclusion and exclusion criteria has limited number of patients.  As our analysis 
does not show different prognosis in overall survival that was determined by 
MGMT methylation or LOH of 1p19q which was shown in more inclusive 
larger patient set, cautious interpretation of our result is required.
13
     From original group of 82 patients, only five of 70 patients tested 
(7.1%) had IDH1 mutations, including one from 27 tMSLC-negative (3.7%) 
and four from 43 tMSLC-positive (9.3%) patients.  While these 5 tumors were 
not clinically suspected as secondary glioblastomas, they were excluded from 
multivariate cox regression model as the entity was shown to have different 
prognosis.38    Patients with mutated IDH1 were younger than those with wild-
type IDH1 (45.3 vs 60.7 years).38 Although LOH at 1p or 19q was found to 
correlate with longer OS in patients with oligodendroglioma45 the association in 
patients with pGBM remains unclear.  In our result, codeletion of 1p19q was 
not associated with prognosis (Univariate: OR=1.3, 95% CI=0.6~3.0, P=0.532, 
Multivariate: OR=1.1, 95% CI=0.4~2.6, P=0.869).  Analysis of MGMT 
promotor showed that 42% of specimens were methylated (41% in tMSLCs(+), 
47% in tMSLCs(-)), and that median OS tended to be longer in patients with 
than without methylation while lacking statistical significance (18.6 vs 15.0 
months, P=0.650).  IHC analysis of p53 found that 28% of specimens were 
stained for this marker.  However, median OS was similar in p53 positive and 
negative patients (18.6 vs 13.7 months, P=0.415).
In this study, tMSLCs were isolated from 58.5% of patients with 
pGBM, compared with 46.2% in a previous study.11  This increase, despite 
using the same isolation method, reemphasizes that isolation of a specific cell 
type from a tumor specimen requires a standardized method or may reflect a 
learning curve among laboratory staffs.  Further research may identify specific 
14
cell markers prognostic of OS.
Mesenchymal features may contribute to poor survival in patients with 
brain tumors.  Higher grade gliomas11 and meningiomas10 are more likely to 
identified to have tMSLCs.  Indeed, tMSLCs could not be isolated from WHO 
grade 1 gliomas and meningiomas, whereas 20%, 33%, and 32% (or 46.2% 
without secondary GBM and recurrent GBM) of WHO grades 2, 3, and 4 
gliomas, respectively, were positive for tMSLCs.11  It remains unclear, however, 
whether the presence of tMSLCs aggravates the natural history of a brain tumor 
or contributes to tumor progression.  
V. Conclusions
Isolation of tMSLCs is associated with the survival of pGBM patients.  tMSLCs 
may have a critical role in the survival of patients with pGBM.  Other cell types 
may predict the clinical course of patients with pGBM.  In addition, cell surface 
markers and molecular markers of pGBM may have prognostic value, and the 
interactions of tMSLCs with gCSCs may better reveal the role of these cell 
types in pGBM patients.  
15
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ABSTRACT(IN KOREAN)
일차성 교모세포종 예후 인자인 종양 간엽줄기유사세포
<지도교수 장종희>
연세대학교 대학원 의학과
윤선진
뇌종양에서 간엽줄기유사세포가 분리된 다는 것은 종양의 시작과
진행에 영향을 주는 미세환경 조성에 이 세포의 영향이 있음을
시사한다. 그러나 일차성 교모세포종 환자에서
간엽줄기유사세포가 분리된 군의 임상적 특성은 지금까지
보고되지 않았다. 이 논문에서는 2009년 4월부터 2014년
10월까지의 82명 환자에서 얻어진 교모세포종 표본을
분석하였다. 생존, 재발, 종양제거 정도 그리고 분자생물학적
표지자 등이 통계적으로 분석되었다. 중위 생존기간은
18.6개월이었고 간엽줄기유사세포 분리군에서는 생존기간이
15.0개월, 비분리군은 29.5개월이었다 (p=0.014). 다중분석을
통해 본 예후인자는 종양 간엽줄기유사세포 분리 (OR=2.5, 95% 
CI=1.1~5.6 p=0.021)와 수술의 정도 (OR=0.5, 95% CI=0.2~0.8, 
p=0.011)가 생존에 영향을 주는 인자들이었다. 일차성
교모세포종에서 종양 간엽줄기유사세포의 분리는 종양의 임상적
진행의 악화 정도와 연관이 있다.
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